1 / 30

Rafael ESTEBAN

Rafael ESTEBAN. New Drugs for Chronic Hepatitis B. R. Esteban, M.D. Hospital General Universitario Valle de Hebron Barcelona. Nucleoside Analogues. Telbivudine.- Novartis/Idenix Emtricitabine (- FTC).- Gilead Science Clevudine (L-FMAU).- Bukwang Pharm. Co

wmolina
Télécharger la présentation

Rafael ESTEBAN

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Rafael ESTEBAN

  2. New Drugs for Chronic Hepatitis B R. Esteban, M.D. Hospital General Universitario Valle de Hebron Barcelona

  3. Nucleoside Analogues • Telbivudine.- Novartis/Idenix • Emtricitabine (- FTC).- Gilead Science • Clevudine (L-FMAU).- Bukwang Pharm. Co • Valtorcitabine (Valyl-L-dC) Idenix-Novartis • Racevir (± FTC).- Pharmasset • Abacavir (GSK) • MIV-210 (FLG) Medivir/GSK

  4. O C H H N 3 O N O H O O H b-L-2’-deoxythymidine (LdT, telbuvidine) Telbivudine (LdT) • Specific inhibitor of HBV polymerase; not active against HIV or other viruses • Favorable preclinical toxicology • Once daily oral dosing indicated by PK • Phase I/II dose escalation results: • Marked HBV suppression after 4 weeks: 3.4 – 3.8 log10 with 400 – 800 mg/day • Excellent safety: no dose-related or dose-limiting toxicities

  5. Efficacy at Week 104 HBeAg-Positive 921 patients (ITT Population) Color designates P < 0.05, telbivudine vs lamivudine at Week 104 Lai CL, and others. Abstract 91. AASLD 2006.

  6. Efficacy at Week 104 HBeAg-Negative 446 Patients (ITT Population) Color designates P < 0.05, telbivudine vs lamivudine at Week 104 Lai CL, and others. Abstract 91. AASLD 2006.

  7. Emtricitabine (FTC) • Cytosine analog, oral 200 mg daily • Structurally similar to Lamivudine (3TC) • Potent activity against HIV and HBV in vitro and in vivo • Drug resistant mutations in YMDD motif • Phase III Clinical Trials

  8. Phase II study. Emtricitabine 200 mg dailyTwo years results in 77 Patients 100 85% 80 53% 60 33% 40 20 0 HBeAg seroconversion HBV DNA negative Normal ALT Drug resistance at year 2: 18% Gish R. J Hepatol 2005;43:60-68

  9. Emtricitabine Monotherapy in Chronic Hepatitis B • FTCB 301: double-blind, placebo-controlled, phase III trial • 248 patients HBeAg positive and negative randomized to receive: • Emtricitabine (200 mg/day) or placebo for 48 wks 100 P<.001 p<.001 p<.001 80 54% 65% 62% 60 40 25% 25% 20 2% 0 Histological Improvement HBV DNA negative <400 copies/mL Normal ALT Seroconversion antiHBe 12% both arms Drug resistance at year 1: 13% LIM SG et AL. Arch Intern Med 2006

  10. Emtricitabine Plus Adefovir • Emtricitabine resistance limits its use as monotherapy • Combination therapy may resolve this issue • FTC-201: double-blind, placebo-controlled, phase II study • 30 HBeAg-positive nucleoside-naive patients • Randomized to adefovir + emtricitabine or adefovir alone Lau G, et al. AASLD 2004. Abstract 245.

  11. Clevudine (L-FMAU) • Thymidine analog • In vitro activity against HBV and EBV but not HIV • Long half-life, more than 40 hours • Phase III study in South Corea

  12. Clevudine Phase 2 Trial Change from baseline serum HBV DNA after 4 weeks treatment 10 mg CLV 50 mg 0.00 100 mg 200 mg -0.50 -1.00 copies/mL) -1.50 Median Change in HBV DNA -2.00 10 -2.50 (log -3.00 -3.50 -4.00 0 2 4 6 12 18 24 28 Weeks 10 mg Cohort n: 5 3 4 4 4 4 4 50 mg Cohort n: 10 10 10 10 8 10 9 100 mg Cohort n: 10 10 10 10 10 10 10 200 mg Cohort n: 7 7 7 7 7 7 7 Marcellin P, Hepatology 2004;40:140-148

  13. Clevudine in HBeAg+ve CHBMulticenter, randomized, phase 3 trialPatients received 24 weeks clevudine 30 mg/day (n = 243) or placebo (n = 61) CLV 30mg PLB CLV 30mg PLB 0 -0.27 HBV DNA (median log10 copies /ml) -1 -0.68 -2 -2.02 -3 -4 -5 -5.10 Week 24 Week 48 (24 weeks off therapy) -6 Yoo et al AASLD 2005

  14. 30 25 20 15 15 12 12 10 10 5 0 Clevudine: phase III study in HBeAg+veHBeAg loss Week 24 Week 48 (24wk off therapy) Patients (%) PLB CLV 30mg CLV 30mg PLB Yoo et al AASLD 2005

  15. Clevudine Treatment in HBeAg-Negative Patients • Multicenter, randomized, phase 3 trial • Patients received 24 weeks clevudine 30 mg/day (n = 63) or placebo (n = 23) • Follow-up, 24 weeks Yoo et al. AASLD 2005. Abstract 183.

  16. Open-Label, Phase III Study of Clevudine: Year 1 results • Clevudine 30 mg/day for 24 weeks, then 10 mg/day through Week 48, then 12 weeks follow-up off treatment (N = 55) • All patients with HBV DNA < 300 copies/mL at Week 24 had sustained virologic, biochemical responses through Week 48 Baseline (Week 0) Treatment End (Week 48) Follow-up (Week 60) 100 100 100 100 100 100 89 86 80 80 68 60 60 Percentage WithHBV DNA < 300 copies/mL Percentage With Normal Serum ALT 40 40 27 25 23 20 20 0 0 0 0 HBeAg-Positive Patients (n = 40) HBeAg-Negative Patients (n = 15) HBeAg-Positive Patients (n = 40) HBeAg-Negative Patients (n = 15) Chung YH, et al. EASL 2006. Abstract 53.

  17. N H O 2 C H N H N 3 O N O N O H O H O O R O O H Telbivudine (LdT) Valtorcitabine (val-LdC) HBV-Specific L-Nucleosides: Valtorcitabine (val-LdC) and Telbivudine (LdT) • Small-molecule HBV polymerase inhibitors • Valtorcitabine is a valine esther prodrug of L-dC (poor bioavailability) • Phosphorylated intracellularly • High intracellular triphosphate concentrations • Renally cleared • HBV-specific • Once daily oral dosing • Favorable toxicology

  18. 900 mg/day Effect of Valtorcitabine on Serum HBV DNA 1 0 Placebo 600 mg/day -1 Serum HBV DNA Mean Log10 Reduction From Baseline 1200 mg/day -2 -3 -4 0 1 2 3 4 5 Study Week Lim SG, et al. EASL 2005.

  19. Valtorcitabine Telbivudine 13 13 13 13 12 12 12 12 11 11 11 11 10 10 10 10 9 9 9 9 8 8 8 8 7 7 7 7 6 6 6 6 5 5 5 5 4 4 4 4 3 0 4 8 12 16 20 24 3 3 3 2 2 2 2 Telbivudine + Valtorcitabine 1 1 1 1 Placebo 0 4 8 12 16 20 24 0 0 4 4 8 8 12 12 16 16 20 20 24 24 Telbivudine and Valtorcitabine are Synergistic in the Woodchuck Model • n = 5 per group • Once daily oral dosing for 12 weeks • Doses (mg/kg/day): • Telbivudine, 10 • Valtorcitabine,10 WHBV DNA Log10 Genome Copies/mL • Potentially complementary mechanisms of action on 1st and 2nd-strand HBV DNA synthesis • Combination has potent synergistic antiviral activity in vitro and in woodchuck HBV model • Both compounds have excellent safety profiles Tennant et al. HepDart 2001 Weeks

  20. Nucleotide Analogues • Tenofovir.- Gilead Sciences • Pradefovir.- Valeant/Schering Plough • Alamifovir.- Eli Lilly • ANA 380.- Anadys Pharmaceuticals

  21. Tenofovir disoproxil fumarate • Acyclic nucleotide approved for HIV infection (as pro-drug TDF) • Anti-hepadnaviral activity in vitro • Potent suppression of HIV and HBV in co-infected patients • Maybe effective against adefovir- and FTC- and ETV-resistant HBV Qi et al. 40th EASL. April 2005. Oral 75

  22. Tenofovir vs Adefovir in patients with lamivudine resistanceHBV-DNA <400 copies/ml Weeks Van Bommel et al 2004

  23. Tenofovir vs Adefovir in LAM-Refractory Patients • Retrospective analysis: LAM-refractory patients switched to tenofovir 300 mg/day (n = 38) or adefovir 10 mg/day (n = 68) • More patients receiving tenofovir exhibited HBeAg and HBsAg loss vs adefovir after up to 2 years van Bömmel F, et al. AASLD 2005. Abstract 184.

  24. Tenofovir Use in Patients With Incomplete Response to Adefovir • Retrospective analysis (N = 20) of tenofovir in patients with chronic hepatitis B who had suboptimal response to adefovir • At tenofovir initiation, the mean HBV DNA was 6.6 log10 copies/mL • Mean changes from baseline in HBV DNA • -3.2 log10 copies/mL (range: -1.4 to -5.7) at 3 months • -3.8 log10 copies/mL (range: -1.4 to -6.7) at 6 months • 18 of 20 (90%) patients achieved HBV DNA < 400 copies/mL after a mean of 4 months (range: 1-9) • 3 patients lost HBeAg after 3-5 months van Bömmel F, et al. AASLD 2005. Abstract 1000.

  25. Pradefovir • Liver-targeting pro-drug of PMEA • activated by the P450 enzyme • CYP3A4 which is expressed exclusively in the liver • In HBV transgenic mouse studies resulted in a 40-fold increase relative to PMEA in drug delivery to the liver • Phase I: HBV DNA reduction at 28 days • - 2 log10 decrease in 5-mg group • - 3 log10 decrease in 60-mg group Remofovir, MB6866 Chao et al, AASLD 2004

  26. Pradefovir for Chronic Hepatitis B: Week 48 Analysis • Phase II randomized, open-label, multicenter trial of ADV-naive patients (N = 244) • Patients received adefovir 10 mg/day or pradefovir 5, 10, 20, or 30 mg/day for 48 weeks • Genotype C: 67% – Asian: 100% – HBeAg positive: 70% Lee KS, et al. EASL 2006. Abstract 741.

  27. Pradefovir for Chronic Hepatitis B: Week 48 Analysis (cont’d) 0 -1 -2 Mean (SE) Change in HBV DNA From Baseline (log10 copies/mL) -3 Pradefovir 5 mg (n = 47) -4.09 -4 Adefovir 10 mg (n = 50) -4.19 Pradefovir 10 mg (n = 49) -4.84 -5 Pradefovir 20 mg (n = 48) -4.89 Pradefovir 30 mg (n = 48) -5.54 -6 0 4 12 18 24 36 48 Week Lee KS, et al. EASL 2006. Abstract 741

  28. Alamifovir • Prodrug of PMEA • Novel mechanism of action? • Interferes with packaging of pregenomic RNA into viral capsids • Dose-ranging study: Reduction in HBV DNA at 28 days in QD or BID regimes: • - 1.52 log10 at 2.5 mg QD • - 2.63 log10 at 10 mg QD LY582563, MCC-478: bis(2,2,2-trifluoroethyl)[(2-{2-amino-6-[(4-methoxyphenyl) sulfanyl]-9H-purin-yl}ethoxy)methyl]phosphonate Soon et al , J Hepatol 2004

  29. ANA380 (LB80380) in HBeAg-Positive Patients With LAM Resistance • Phase II, multicenter, dose-escalating study (N = 65) • HBeAg-positive Asian patients • 5 dose escalation groups • ANA380 (30, 60, 90, 150, or 240 mg/day) + LAM for 4 weeks followed by 8 weeks ANA380 monotherapy ANA380 Dose 30 (n = 13) 60 (n = 14) 90 (n = 14) 150 (n = 12) 240 (n = 12) 0 -1 Reduction in HBV DNA by Week 12 (log10 copies/mL) -2 -3 -2.8 -3.2 -4 -3.9 -3.9 -4.1 -5 Lai CL, et al. EASL 2006.

  30. Combination therapy for CH-B • Different targets or mechanisms • Goals, more effective in • Suppression of HBV replication • Induction of HBeAg seroconversion • Durable post-treatment responses • Reduction of drug-resistant mutants

More Related